GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Net-Net Working Capital

HURA (TuHURA Biosciences) Net-Net Working Capital : $-0.05 (As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

TuHURA Biosciences's Net-Net Working Capital for the quarter that ended in Dec. 2023 was $-0.05.

The industry rank for TuHURA Biosciences's Net-Net Working Capital or its related term are showing as below:

HURA's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.5
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

TuHURA Biosciences Net-Net Working Capital Historical Data

The historical data trend for TuHURA Biosciences's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Net-Net Working Capital Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23
Net-Net Working Capital
-0.04 0.27 -0.05

TuHURA Biosciences Semi-Annual Data
Dec21 Dec22 Dec23
Net-Net Working Capital -0.04 0.27 -0.05

Competitive Comparison of TuHURA Biosciences's Net-Net Working Capital

For the Biotechnology subindustry, TuHURA Biosciences's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TuHURA Biosciences's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where TuHURA Biosciences's Price-to-Net-Net-Working-Capital falls into.


TuHURA Biosciences Net-Net Working Capital Calculation

TuHURA Biosciences's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3.665+0.75 * 0+0.5 * 0-5.921
-0.008-0)/42.030
=-0.05

TuHURA Biosciences's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

Net-Net Working Capital(Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3.665+0.75 * 0+0.5 * 0-5.921
-0.008-0)/42.030
=-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

TuHURA Biosciences  (NAS:HURA) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.

TuHURA Biosciences Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Net-Net Working Capital
Comparable Companies
Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
Website
https://www.tuhurabio.com
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.